文献速递肾小球疾病

应用伊米苷酶阐明抗GBM抗体在治疗开始后产生的特征与重要性

Using imlifidase to elucidate the characteristics and importance of anti-GBM antibodies produced after start of treatment.
PubMed 文献 · Nephrol Dial Transplant · 2023-01-01

GOOD-IDES-01试验纳入15例抗GBM病患者,使用伊米苷酶清除IgG后前瞻性随访6个月,分析抗体表位特异性、IgG亚类及ANCA。抗体反弹者6个月eGFR趋于更低(11 vs 34 mL/min/1.73 m2,P=.055),6个月透析者反弹时EB/EA比值更高(0.8 vs 0.5,P=.047)。结论认为抗GBM抗体反弹尤其针对EB表位与更差结局相关。

要点

  • 抗体反弹者6个月eGFR趋于更低(11 vs 34 mL/min/1.73 m2,P=.055)。
  • 6个月透析者反弹时EB/EA比值更高(0.8 vs 0.5,P=.047)。
  • 伊米苷酶可早期和长期清除ANCA,仅1例6个月时ANCA仍阳性。

核心结论

  • 抗GBM抗体反弹尤其针对EB表位时与更差结局相关,支持采用一切手段清除抗GBM抗体。

研究设计与样本

  • GOOD-IDES-01试验(NCT03157037)中15例抗GBM患者接受伊米苷酶治疗,前瞻性收集6个月血清样本。

主要发现

  • 抗体反弹者(n=10)6个月eGFR趋于更低(11 vs 34 mL/min/1.73 m2,P=.055)。
  • 6个月透析者反弹时EB/EA比值更高(0.8 vs 0.5,P=.047)。
  • 2例患者表位限制性增加,数例患者反弹时IgG亚类分布发生转变。
  • 6例患者ANCA双阳性,50%患者出现ANCA反弹,仅1例6个月时ANCA仍阳性。

关键数值与推荐

  • 反弹者6个月eGFR 11 vs 非反弹者34 mL/min/1.73 m2,P=.055。
  • 6个月透析者反弹时EB/EA比值0.8 vs 非透析者0.5,P=.047。

临床怎么用

  • 作者认为应采用一切手段清除抗GBM抗体。
  • 本研究中伊米苷酶和环磷酰胺可早期和长期清除ANCA。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Autoantibodies are common in glomerulonephritis, but the clinical benefit of rapid elimination has not been determined, even in anti-glomerular basement membrane (GBM) disease. Even less is known about the importance of autoantibody characteristics, including epitope specificity and immunoglobulin G (IgG) subclass distribution. We aimed to address this by characterizing the autoantibody profile in anti-GBM patients: we utilized samples from the GOOD-IDES-01 (treating GOODpasture's disease with Imunoglobulin G Degrading Enzyme of Streptococcus pyogenous) (ClinicalTrials.gov identifier: NCT03157037) trial , where imlifidase, which cleaves all IgG in vivo within hours, was given to 15 anti-GBM patients. METHODS: In the GOOD-IDES-01 trial, plasmapheresis was (re)started if anti-GBM antibodies rebounded. Serum samples were collected prospectively for 6 months and analyzed for anti-GBM epitope specificity using recombinant constructs of the EA and EB epitopes, IgG subclass using monoclonal antibodies, and anti-neutrophil cytoplasmic antibodies (ANCA). The results were correlated with clinical data. RESULTS: Patients with a rebound (n = 10) tended to have lower eGFR at 6 months (11 vs 34 mL/min/1.73 m2, P = .055), and patients with dialysis at 6 months had a higher EB/EA ratio at rebound (0.8 vs 0.5, P = .047). Moreover, two patients demonstrated increasing epitope restriction and several patients displayed a shift in subclass distribution at rebound. Six patients were double positive for ANCA. ANCA rebound was seen in 50% of patients; only one patient remained ANCA positive at 6 months. CONCLUSIONS: In this study, rebound of anti-GBM antibodies, especially if directed against the EB epitope, was associated with a worse outcome. This supports the notion that all means should be used to eliminate anti-GBM antibodies. In this study ANCA was removed early and long-term by imlifidase and cyclophosphamide.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Tyrberg L, Andersson F, Uhlin F, et al. Using imlifidase to elucidate the characteristics and importance of anti-GBM antibodies produced after start of treatment. Nephrol Dial Transplant. 2023. PMID: 37385828. doi:10.1093/ndt/gfad132

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。